What Does the Research Say About Ozempic and Gastroparesis?

Latest update (2026-01)

FDA enforcement record (Ongoing): Presence of Particulate Matter: Hair was found in a prefilled syringe. [source]

From General Health Literacy to Targeted Risk Awareness

If you or someone you know has experienced persistent nausea, vomiting, or abdominal pain while taking Ozempic, you may be wondering about the connection to gastroparesis. Building on decades of pharmacovigilance research, this update summarizes published case reports and FDA labeling information to clarify what is currently known about this potential side effect.

The Medical Link Between Ozempic and Gastroparesis

Ozempic (semaglutide) is a glucagon-like peptide-1 (GLP-1) receptor agonist approved for the treatment of type 2 diabetes mellitus. Its pharmacological action includes slowing gastric emptying, which is a known mechanism that can contribute to gastrointestinal adverse effects. Among these, gastroparesis—a condition characterized by delayed gastric emptying in the absence of mechanical obstruction—has emerged as a significant concern. Clinical presentation of gastroparesis includes nausea, vomiting, early satiety, bloating, and abdominal pain, which overlap with common side effects reported in Ozempic clinical trials. In placebo-controlled trials, gastrointestinal adverse reactions occurred more frequently among patients receiving Ozempic than placebo (placebo 15.3%, Ozempic 0.5 mg 32.7%, Ozempic 1 mg 36.4%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). Nausea was reported in 6.1% of placebo patients versus 15.8% for Ozempic 0.5 mg and 20.3% for Ozempic 1 mg; vomiting occurred in 2.3% of placebo patients versus 5.0% and 9.2% for the respective doses (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). These symptoms are hallmark features of gastroparesis, and their dose-dependent increase suggests a mechanistic link between semaglutide and impaired gastric motility.

Mechanistic Evidence and Warning Adequacy

The mechanistic pathway connecting Ozempic to gastroparesis involves the drug's effect on GLP-1 receptors in the gastrointestinal tract. GLP-1 receptor agonists delay gastric emptying by inhibiting antral contractions and stimulating pyloric tone, which can lead to retained gastric contents. This effect is supported by postmarketing reports of pulmonary aspiration in patients undergoing elective surgeries or procedures requiring general anesthesia or deep sedation, who had residual gastric contents despite reported adherence to preoperative fasting recommendations (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=27f15fac-7d98-4114-a2ec-92494a91da98). Such reports underscore the potential for clinically significant gastroparesis, as retained gastric contents indicate delayed emptying that can persist even after drug discontinuation. The label notes that available data are insufficient to inform recommendations to mitigate the risk of pulmonary aspiration, including whether modifying preoperative fasting or temporarily discontinuing the drug could reduce the incidence of retained gastric contents (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=27f15fac-7d98-4114-a2ec-92494a91da98). This highlights a gap in understanding the duration of gastroparesis after Ozempic exposure. From a risk perspective, the adequacy of warnings regarding Ozempic and gastroparesis is a critical issue. The prescribing information for Ozempic lists gastrointestinal adverse reactions as common, but it does not explicitly warn about gastroparesis as a distinct condition. Instead, symptoms such as nausea, vomiting, and abdominal pain are grouped under general gastrointestinal adverse reactions (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). The label also includes a warning about hypersensitivity reactions, including anaphylaxis and angioedema, but does not address the potential for prolonged gastric emptying or gastroparesis (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). This omission may leave patients and healthcare providers unaware of the risk for developing a chronic condition that can severely impact quality of life. For affected patients, this raises questions about whether the manufacturer provided sufficient information to allow informed decision-making.

Statute of Limitations for Ozempic Claims in Massachusetts

Attorney-related considerations for patients in Massachusetts who have developed gastroparesis after using Ozempic involve the statute of limitations. In Massachusetts, the statute of limitations for personal injury claims, including those related to defective drugs, is generally three years from the date of injury or from when the injury was discovered or should have been discovered. For gastroparesis, the timeline between exposure to Ozempic and documented harm can vary. Symptoms may develop during dose escalation, as noted in clinical trials where the majority of nausea, vomiting, and diarrhea occurred during dose escalation (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). However, gastroparesis can also manifest after prolonged use or even after discontinuation, making it challenging to pinpoint the exact date of injury. Patients who experience persistent gastrointestinal symptoms should seek medical evaluation to confirm a diagnosis of gastroparesis, as this documentation is essential for legal claims. The statute of limitations clock may start ticking from the date of diagnosis or from when a reasonable person would have connected the symptoms to Ozempic use. In summary, the evidence indicates a plausible link between Ozempic and gastroparesis through its mechanism of delaying gastric emptying, supported by clinical trial data showing high rates of nausea and vomiting. The adequacy of warnings is questionable, as the label does not specifically address gastroparesis. Patients in Massachusetts should be aware of the three-year statute of limitations and the importance of timely medical and legal consultation. The timeline from exposure to harm can be variable, emphasizing the need for careful documentation of symptoms and drug use.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the statute of limitations for filing an Ozempic gastroparesis lawsuit in Massachusetts?

In Massachusetts, the statute of limitations for personal injury claims, including defective drug claims, is generally three years from the date of injury or from when the injury was discovered or should have been discovered. For gastroparesis, this may be the date of diagnosis or when a reasonable person would connect symptoms to Ozempic use.

Does Ozempic's label warn about gastroparesis?

No, the prescribing information for Ozempic lists gastrointestinal adverse reactions such as nausea and vomiting as common, but it does not explicitly warn about gastroparesis as a distinct condition. This omission may affect informed consent and legal claims regarding inadequate warnings.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Ozempic exposure and a confirmed Gastroparesis diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.